Jonathan Mandelbaum
About Jonathan Mandelbaum
Jonathan Mandelbaum serves as Vice President at OrbiMed in New York, a position he has held since 2022. He has a strong background in drug discovery and venture capital, with a Ph.D. from Columbia University and experience at various leading organizations in the healthcare sector.
Work at OrbiMed Advisors
Jonathan Mandelbaum has served as Vice President at OrbiMed Advisors since 2022. He previously held the position of Senior Associate at the same firm from 2020 to 2022. His role at OrbiMed focuses on venture capital in the healthcare sector, leveraging his extensive background in drug discovery to inform investment decisions and strategies.
Education and Expertise
Jonathan Mandelbaum earned his Ph.D. in Cellular, Molecular and Biophysical Studies from Columbia University, completing his studies with distinction from 2005 to 2010. He also holds a Bachelor of Science degree in Biology from McGill University, where he graduated with great distinction in 2005. His educational background provides a strong foundation for his expertise in drug discovery and venture capital.
Background
Before joining OrbiMed, Jonathan Mandelbaum worked in various roles that contributed to his expertise in the life sciences. He was a Postdoctoral Fellow at Takeda Oncology from 2011 to 2013 and at Columbia University Medical Center from 2010 to 2011. Additionally, he served as a Graduate Research Assistant at Columbia University Medical Center from 2005 to 2010, where he gained significant research experience.
Previous Experience in Healthcare
Jonathan Mandelbaum has a diverse professional background in the healthcare sector. He worked as a Scientist I at Takeda Oncology from 2013 to 2015 and held positions at Accelerator Life Science Partners, first as an Associate from 2015 to 2017 and then as Principal from 2017 to 2020. These roles allowed him to transition from scientific research to leadership in venture capital.
Passion for Innovative Medicines
Jonathan Mandelbaum is passionate about developing innovative medicines to treat human diseases. This commitment drives his work in venture capital, where he aims to support the advancement of healthcare solutions through strategic investments in promising life sciences companies.